نتایج جستجو برای: ژن kras

تعداد نتایج: 23037  

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2011
Peter P Grimminger Peter Danenberg Kathrin Dellas Dirk Arnold Claus Rödel Jean-Pascal Machiels Karin Haustermans Annelies Debucquoy Vaneja Velenik Christine Sempoux Matej Bracko Arnulf H Hölscher Robert Semrau Dongyun Yang Kathleen Danenberg Heinz-Josef Lenz Daniel Vallböhmer

PURPOSE Phase II trials in locally advanced rectal cancer have shown that cetuximab-based neoadjuvant radiochemotherapy is feasible but without an improvement in complete pathologic response rates. Our goal was to identify patients who would benefit from cetuximab-based neoadjuvant chemoradiation measuring gene expression levels of proteins involved in tumor growth [endothelial growth factor re...

Journal: :Oncology reports 2009
Zhi-Min Liu Li-Na Liu Mei Li Qiu-Ping Zhang Shi-Hua Cheng Shen Lu

KRAS proteins play an important role in regulating cell functions. A series of studies has revealed that mutations of KRAS are involved in gastric carcinogenesis. However, mutation status of KRAS remains unclear in gastric cancer from Chinese Mainland. It has been proved that KRAS mutation associates with resistance to epidermal growth factor receptor (EGFR) inhibitors. In this study, KRAS muta...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2015
Bing Yu Stephen Swatkoski Alesia Holly Liam C Lee Valentin Giroux Chih-Shia Lee Dennis Hsu Jordan L Smith Garmen Yuen Junqiu Yue David K Ann R Mark Simpson Chad J Creighton William D Figg Marjan Gucek Ji Luo

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D growth of KRAS mutant colorectal cancer cells in vitro and attenuates tumor growth in vivo. In KRAS...

Journal: :CPT: pharmacometrics & systems pharmacology 2018
Edward C Stites Andrey S Shaw

KRAS has proven difficult to target pharmacologically. Two strategies have recently been described for covalently targeting the most common KRAS mutant in lung cancer, KRAS G12C. Previously, we developed a computational model of the processes that regulate Ras activation. Here, we use this model to investigate KRAS G12C covalent inhibitors. We updated the model to include Ras protein turnover, ...

Journal: :Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2015
Chen Wu Sihan Wang Caihua Xu Andreas Tyler Xingru Li Charlotta Andersson Yusuke Oji Haruo Sugiyama Yijiang Chen Aihong Li

BACKGROUND A novel link between oncogenic KRAS signalling and WT1 was recently identified. We sought to investigate the role of WT1 and KRAS in proliferation and apoptosis. METHODS KRAS mutations and WT1 (cMyc) expression were detected using Sanger sequencing and real-time PCR in 77 patients with non-small cell lung cancer (NSCLC). Overexpression and knockdown of WT1 were generated with plasm...

Journal: :Cancer research 2011
Carol Babij Yihong Zhang Robert J Kurzeja Anke Munzli Amro Shehabeldin Manory Fernando Kim Quon Paul D Kassner Astrid A Ruefli-Brasse Vivienne J Watson Flordeliza Fajardo Angela Jackson James Zondlo Yu Sun Aaron R Ellison Cherylene A Plewa Miguel Tisha San John Robinson John McCarter Ralf Schwandner Ted Judd Josette Carnahan Isabelle Dussault

Despite the prevalence of KRAS mutations in human cancers, there remain no targeted therapies for treatment. The serine-threonine kinase STK33 has been proposed to be required for the survival of mutant KRAS-dependent cell lines, suggesting that small molecule kinase inhibitors of STK33 may be useful to treat KRAS-dependent tumors. In this study, we investigated the role of STK33 in mutant KRAS...

2017
Inna Chen Victoria M. Raymond Jennifer A. Geis Eric A. Collisson Benny V. Jensen Kirstine L. Hermann Mark G. Erlander Margaret Tempero Julia S. Johansen

Precision oncology requires sensitive and specific clinical biomarkers. Carbohydrate Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks sensitivity and specificity. Nearly all PDAs harbor somatic KRAS mutations, nominating circulating tumor DNA (ctDNA) KRAS as an alternative disease biomarker, however, variable clinical performance has limited its clinical ...

Journal: :Molecular cancer research : MCR 2015
Koichi Okamoto Aziz Zaanan Hisato Kawakami Shengbing Huang Frank A Sinicrope

UNLABELLED KRAS mutations are frequently detected in human colorectal cancer and contribute to de novo apoptosis resistance and ultimately therapeutic failure. To overcome KRAS-mediated apoptosis resistance, the irreversible proteasome inhibitor, carfilzomib, was evaluated and found to potently induce Noxa, which was dependent upon c-Myc, and Bik. Isogenic mutant versus wild-type KRAS carcinoma...

2016
Kosuke Toda Kenji Kawada Masayoshi Iwamoto Susumu Inamoto Takehiko Sasazuki Senji Shirasawa Suguru Hasegawa Yoshiharu Sakai

A number of clinical trials have shown that KRAS mutations of colorectal cancer (CRC) can predict a lack of responses to anti-epidermal growth factor receptor-based therapy. Recently, there have been several studies to elucidate metabolism reprogramming in cancer. However, it remains to be investigated how mutated KRAS can coordinate the metabolic shift to sustain CRC tumor growth. In this stud...

Background: Mutations in the EGFR signaling pathway play an important role in the development of colorectal cancer (CRC). Mutations in these genes, like KRAS and BRAF, affect the treatment strategies and associated with poor prognosis and relative resistance to anti-EGFR therapies. Our aim was to conduct a systematic and meta-analysis on all studies that have been conducted on the prevalence of...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید